Brielle Benyon

Progression-free survival lengths were different among patients with non-small cell lung cancer receiving sotorasib when stratified by genomic profile.

Close monitoring for neurologic toxicity resulted in no long-term effects in a patient cohort treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Subcutaneous Elranatamab had high response rates when given at or above 215 μg/kg.

While survival rates were similar, acalabrutinib had lower rates of atrial fibrillation and other adverse events than ibrutinib for previously treated CLL.

Data from 2 clinical trials proved that larotrectinib is efficacious and safe in treating adults and children with NTRK fusion-positive central nervous system cancers.

Survival outcomes improved when nivolumab was added to either ipilimumab or chemotherapy versus chemotherapy alone in advanced/metastatic esophageal squamous cell carcinoma

A presentation at the recent 46th Annual Oncology Nursing Society’s Annual Meeting focused on ethical dilemmas facing oncology nurses and how clinicians are managing them.

Nurse Navigator Janeen Bazan, RN, OCN, BSN, talks about the 4R Care Sequence® and its impact on the care of patients with breast cancer at the 2021 Oncology Nursing Society Annual Congress.

According to the research, there are important components and factors missing from the scale commonly used to measure a clinician’s quality of life.

Improving patient care may be possible for institutions achieving Disease-Specific Care certifications with certified nurse specialists at the helm.

High response rates with novel eganelisib plus PD-1 inhibition is reported in patients with metastatic urothelial carcinoma, especially those with low PD-L1 expression.

Results from the 2020 World Conference on Lung Cancer Singapore demonstrated the feasibility of using STK11 mutations and immune-related adverse events as response predictors in patients with non–small cell lung cancer.

Cancertrialsearch.com helped to match patients with gastrointestinal cancers to clinical trials using 7 different criteria, possibly paving the way for patients to find, understand, and enroll in oncology clinical trials.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

A recent study found a difference in preference when it came to the administration of rituximab in patients with blood cancer.

Study results suggested that while chemotherapy-induced nausea/vomiting (CINV) can be treated, there is potential for it to return, especially for patients for whom CINV treatment did not work the first time around.

The study found that that weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer with regard to progression-free survival and overall survival.

Recent study results revealed the most prevalent concerns of oncology nurses during the coronavirus disease 2019 outbreak

Despite a recent surge in the need for and use of telemedicine, in home infusions are still not recommended.

A proposed bill in the US House of Representatives would get rid of debt for healthcare workers who are treating COVID-19 patients.

A palliative care and advanced planning nurse discusses tips on delivering the best care to patients during the COVID-19 pandemic

A study presented at the 2020 ASCO Virtual Scientific Program showed nurse-led triage reduced hospitalizations for cancer patients.

Teclistamab appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at the ASCO Virtual Scientific Program.

According to the largest phase III trial examining BTK inhibitors for patients with Waldenström macroglobulinemia, zanubrutinib appears to be associated with higher complete response or very good partial response, as well as clinically meaningful advantages in safety and tolerability compared to ibrutinib.

This is the first FDA approval for this patient population.